The Patient Role in Stimulating Chronic Fatigue Syndrome Drug Development
This article was originally published in RPM Report
The Food & Drug Administration convened a two-day meeting with CFS patients, advocates, clinicians and researchers in late April. One of the speakers invited by FDA was former Lilly corporate strategy exec Bernard Munos. His presentation was part exhortation, part reality check – delivering in straightforward, practical terms how patient groups can step into the drug development process to deliver data for regulators and commercial developers. Here is a transcript of his remarks, lightly edited for clarity.